



RANDAL R. JONES
(206) 903-8814
FAX (206) 903-8820
JONES.RANDAL@DORSEY.COM

June 26, 2009

Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7010

Re: OncoGenex Pharmaceuticals — Registration Statement on Form S-3 (File No. 333-160251) filed on June 26, 2009

Dear Sir or Madam,

In connection with the Registration Statement on Form S-3 (file no. 333-160251) filed on June 26, 2009 by OncoGenex Pharmaceuticals, Inc., we are furnishing the correspondence attached as Exhibit A required under National Instrument 71-101.

Very truly yours,

/s/ Randal R. Jones
Randal R. Jones

DORSEY & WHITNEY LLP · WWW.DORSEY.COM · T 206.903.8800 · F 206.903.8820
U.S. BANK CENTRE · 1420 FIFTH AVENUE · SUITE 3400 · SEATTLE, WASHINGTON 98101-4010

USA CANADA EUROPE ASIA

EXHIBIT A

NOTICE OF FILING PURSUANT TO NATIONAL INSTRUMENT 71-101
The Multijurisdictional Disclosure System

TO: British Columbia Securities Commission

AND TO: The United States Securities and Exchange Commission

RE: OncoGenex Pharmaceuticals, Inc. (the "Company")

The Company has today filed a preliminary MJDS prospectus dated June 26, 2009, pursuant to National Instrument 71-101, *The Multijurisdictional Disclosure System* ("NI 71-101"), and designates the British Columbia as the principal jurisdiction in Canada.

DATED June 26, 2009.

ONCOGENEX PHARMACEUTICALS, INC.

/s/ Scott Cormack

Scott Cormack
President and Chief Executive Officer